Controversies Concerning Vitamin K and the Newborn

ABSTRACT. Prevention of early vitamin K deficiency bleeding (VKDB) of the newborn, with onset at birth to 2 weeks of age (formerly known as classic hemorrhagic disease of the newborn), by oral or parenteral administration of vitamin K is accepted practice. In contrast, late VKDB, with onset from 2 to 12 weeks of age, is most effectively prevented by parenteral administration of vitamin K. Earlier concern regarding a possible causal association between parenteral vitamin K and childhood cancer has not been substantiated. This revised statement presents updated recommendations for the use of vitamin K in the prevention of early and late VKDB.

ABBREVIATION. VKDB, vitamin K deficiency bleeding.

BACKGROUND

Vitamin K deficiency may cause unexpected bleeding (0.25%–1.7% incidence) during the first week of life in previously healthy-appearing neonates (early vitamin K deficiency bleeding [VKDB] of the newborn [formerly known as classic hemorrhagic disease of the newborn]). The efficacy of neonatal vitamin K prophylaxis (oral or parenteral) in the prevention of early VKDB is firmly established. It has been the standard of care since the American Academy of Pediatrics recommended it in 1961.1

Late VKDB, a syndrome defined as unexpected bleeding attributable to severe vitamin K deficiency in infants 2 to 12 weeks of age, occurs primarily in exclusively breastfed infants who have received no or inadequate neonatal vitamin K prophylaxis. In addition, infants who have intestinal malabsorption defects (cholestatic jaundice, cystic fibrosis, etc) may also have late VKDB. The rate of late VKDB (often manifesting as sudden central nervous system hemorrhage) ranges from 4.4 to 7.2 per 100 000 births, according to reports from Europe and Asia.2,3 When a single dose of oral vitamin K has been used for neonatal prophylaxis, the rate has decreased to 1.4 to 6.4 per 100 000 births. Parenteral neonatal vitamin K prophylaxis prevents the development of late VKDB in infants, with the rare exception of those with severe malabsorption syndromes.2

Oral administration of vitamin K has been shown to have efficacy similar to that of parenteral administra-
Recent research on the pathogenesis of childhood leukemia additionally weakens the plausibility of a causal relationship between parenteral administration of vitamin K and cancer. Investigations by Wiemels et al.\(^1^5\) suggest a prenatal origin of childhood leukemia. They found an acute lymphocytic leukemia-associated gene in 12 children with newly diagnosed acute lymphocytic leukemia and postulated that an in utero chromosomal translocation event combined with a postnatal promotional event results in clinical leukemia. Although intramuscular administration of vitamin K could conceivably be a postnatal promotional event, a genetic etiologic explanation further lessens the likelihood of a clinically significant relationship between intramuscular administration of vitamin K and leukemia.

There is concern that adequate vitamin K prophylaxis be provided to the increasing numbers of newborns who are breastfed exclusively to avoid an increased risk of late VKDB with its associated intracranial hemorrhage.\(^7\)

**RECOMMENDATIONS**

Because parenteral vitamin K has been shown to prevent VKDB of the newborn and young infant and the risks of cancer have been unproven, the American Academy of Pediatrics recommends the following:

1. Vitamin K\(_1\) should be given to all newborns as a single, intramuscular dose of 0.5 to 1 mg.\(^1^6\)
2. Additional research should be conducted on the efficacy, safety, and bioavailability of oral formulations and optimal dosing regimens of vitamin K to prevent late VKDB.
3. Health care professionals should promote awareness among families of the risks of late VKDB associated with inadequate vitamin K prophylaxis from current oral dosage regimens, particularly for newborns who are breastfed exclusively.

**COMMITTEE ON FETUS AND NEWBORN, 2002–2003**

Lillian Blackmon, MD, Chairperson
Daniel G. Batton, MD
Edward F. Bell, MD
William A. Engle, MD
William P. Kantor, Jr, MD
Gilbert J. Martin, MD
Warren Rosenfeld, MD
Ann R. Stark, MD

*Carol A. Miller, MD
Past Committee Member

**LIAISONS**

Keith J. Barrington, MD
Canadian Paediatric Society

Torse Raju, MD, DCH
National Institutes of Health
Laura E. Riley, MD
American College of Obstetricians and Gynecologists
Kay M. Tomashek, MD
Centers for Disease Control and Prevention
Carol Wallman, MSN, RNC, NNIF
National Association of Neonatal Nurses

**STAFF**

Jim Couto, MA

*Lead author

**REFERENCES**

Controversies Concerning Vitamin K and the Newborn
Committee on Fetus and Newborn

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://pediatrics.aappublications.org/content/112/1/191